Regulatory Approval

New research reveals how IntraBio's AQNEURSA recalibrates cellular function, a novel mechanism that could revolutionize treatment for a wide range of diseases.

With regulatory approval secured, Hancock Whitney's $377.6M acquisition of One Florida Bank is set to reshape the state's banking landscape.

After a multi-year effort, the cybersecurity firm can now bid on top-secret defense contracts, a move that could transform its future.

After a two-year engagement, Galaxy Gaming's merger with Evolution is stalled by regulatory hurdles. Frank Reed analyzes a deal teetering on the brink.

With FDA Fast Track and a key ESMO presentation, Nouscom is de-risking its pioneering cancer interception therapy, NOUS-209, for Lynch Syndrome.

With its new DBS certification, AU10TIX consolidates UK digital identity checks, simplifying compliance and reshaping how we verify who people are.

Medtrum's new 300U patch pump enters Germany's key market, challenging rivals with higher capacity and a fully integrated system for patient-centric care.

As BitDelta Securities plants its flag in Dubai with a full CMA license, it's not just another market entry; it's a bet on a hybrid future of finance.

Bausch + Lomb's EyeGility system aims to make cataract surgery faster and safer. A look at the tech, the competition, and the push for efficiency.

As demand for battle-proven drones soars, AIRO’s major RQ-35 delivery proves that controlling the entire supply chain is the key to winning in defense.

Graphite One's Ohio facility clears a key regulatory hurdle, accelerating a plan to build the first fully integrated US graphite supply chain.

With mortality rates over 50%, cardiogenic shock has long eluded targeted treatment. Now, a novel antibody from 4TEEN4 gets an FDA fast track.

As Europe's MiCA regulation wipes out 90% of crypto firms, Singaporean-founded Paymonade emerges as a key builder of the new, compliant financial plumbing.

In a landmark move, DTCC successfully tokenized U.S. securities, proving institutional finance can adopt blockchain to unlock unprecedented market liquidity.

A new bispecific antibody from Kelun-Biotech and Harbour BioMed just got a green light in China, promising quarterly doses for asthma. Is this the innovation that finally unseats the market giants?

Genentech's Gazyva gains FDA Priority Review for a rare kidney disease with no approved treatments, signaling a potential paradigm shift for patients.

With new launches in Austin and Cleveland and a C-suite of Tesla, Waymo, and Uber vets, Zipline is rapidly scaling its autonomous delivery empire.

With a new one-hour test for deadly bloodstream infections, QIAGEN aims to arm clinicians in the fight against sepsis and antimicrobial resistance.

A key approval for a single raw material in Japan reveals the new frontier in biopharma: a global race for regulatory compliance that could fast-track cell therapies.

As AT&T plans to end new landline orders in California, a fierce debate erupts over public safety, consumer choice, and the future of essential services.